- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.05. | Day One Biopharmaceuticals, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 23.04. | Servier Acquires Day One Biopharmaceuticals | 9 | Contract Pharma | ||
| 23.04. | Servier completes the acquisition of Day One Biopharmaceuticals | 440 | PR Newswire | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of... ► Artikel lesen | |
| 23.04. | NSE - Day One Biopharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 23.04. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 13.03. | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 3.334 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| 11.03. | JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition | 6 | Investing.com | ||
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.03. | This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday | 2 | Benzinga.com | ||
| 09.03. | Servier acquires International Biotech's Day One Biopharmaceuticals for USD2.5 billion | 3 | Alliance News | ||
| 09.03. | Intnl. Biotechnology - Portfolio company Day One Biopharmaceuticals acquired by Servier | 1 | RNS | ||
| 07.03. | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 24 | Seeking Alpha | ||
| 07.03. | Day One Biopharmaceuticals (DAWN) Climbs to 3-Year High on $2.5-Billion Merger | 1 | Insider Monkey | ||
| 06.03. | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 13 | MedCity News | ||
| 06.03. | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| 06.03. | Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio | 2 | Contract Pharma | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | 1 | BioPharma Dive | ||
| 06.03. | TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal | 3 | Investing.com | ||
| 06.03. | Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal | 2 | Investing.com | ||
| 06.03. | Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday | 5 | Benzinga.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,05 | -0,38 % | Milliardenmarkt psychische Gesundheit: Unentdecktes Small-Cap vs. Big-Pharma wie Bayer, Novo Nordisk und BioNTech | ||
| AMGEN | 294,00 | -0,17 % | MariTide-Ausblick: Mizuho hebt Amgen-Kursziel auf 303 US-Dollar an | ||
| NOVAVAX | 8,010 | +0,50 % | Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade | ||
| BIOGEN | 170,66 | -0,52 % | Biogen Inc.: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,840 | -0,70 % | Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year | ||
| VIKING THERAPEUTICS | 26,200 | -1,32 % | Is Viking Therapeutics Stock Going to $100? | ||
| INTELLIA THERAPEUTICS | 13,320 | -2,63 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 43,495 | -1,94 % | Should You Retain Tempus AI Stock In Your Portfolio Now? | ||
| BIOCRYST PHARMACEUTICALS | 8,006 | +2,09 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 47,570 | -1,49 % | BioMarin legt überzeugende Dreijahresdaten für VOXZOGO bei Hypochondroplasie vor | ||
| EXELIXIS | 44,965 | -0,76 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,320 | 0,00 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,188 | -2,46 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,936 | +0,65 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting | Urges Stockholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen |
DAY ONE BIOPHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,21 % bei einem Aktienkurs von 21,530 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.